



July 10, 2024

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 10, 2024 titled **“Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



## **Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg**

*Ahmedabad, India, 10 July, 2024*

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Diroximel Fumarate Delayed-Release Capsules, 231 mg (USRLD: Vumerity® Delayed-Release Capsules tablets).

Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.

Diroximel Fumarate Delayed-Release Capsules had annual sales of USD 847.4 mn in the United States (IQVIA MAT May 2024).

The group now has 398 approvals and has so far filed over 460\* ANDAs since the commencement of the filing process in FY 2003-04.

*(\*as of 31<sup>st</sup> March 2024)*

\*\*\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878